Rai Bhavana, Ghoshal Sushmita, Sharma Suresh C
Department of Radiotherapy, Post Grade Institute of Medical Education and Research, Chandigarh, India.
J Cancer Res Ther. 2005 Jan-Mar;1(1):31-3. doi: 10.4103/0973-1482.16087.
Male breast cancer is a rare disease representing 1% of all breast cancers and less than 1% of all cancers in men. Because of its rarity, carcinoma breast has not been studied extensively and this prompted us to carry out this retrospective study. The aim of the study was to observe the clinical and pathological features, evaluate the prognostic factors and to co-relate the outcome in patients of male breast cancer.
Thirty patients of male breast cancer treated in the department of radiotherapy from year 1996-2000 were retrospectively analyzed.
The actuarial five- year disease free survival was 40%. Three out of 30 i.e. 10% patients had loco-regional recurrence and all of them had locally advanced disease at presentation. Distant metastasis occurred in 9 patients of whom 6 patients had T3-T4 tumor and 1 patient had T1-T2 tumor.
Modified radical mastectomy followed by external radiation therapy is the standard treatment for male breast cancer. Hormone therapy, as an adjuvant treatment, is the first line approach in a majority of patients and chemotherapy is reserved for patients with poor prognostic factors.
男性乳腺癌是一种罕见疾病，占所有乳腺癌的1%，占男性所有癌症的比例不到1%。由于其罕见性，乳腺癌尚未得到广泛研究，这促使我们开展这项回顾性研究。本研究的目的是观察男性乳腺癌患者的临床和病理特征，评估预后因素，并关联其预后情况。
回顾性分析了1996年至2000年在放疗科接受治疗的30例男性乳腺癌患者。
精算的五年无病生存率为40%。30例中有3例（即10%）患者出现局部区域复发，且所有这些患者在初诊时均为局部晚期疾病。9例患者发生远处转移，其中6例患者为T3 - T4期肿瘤，1例患者为T1 - T2期肿瘤。
改良根治性乳房切除术加外照射是男性乳腺癌的标准治疗方法。激素治疗作为辅助治疗，是大多数患者的一线治疗方法，化疗则适用于预后因素较差的患者。
